Eli Lilly is expanding its AI-driven drug discovery collaboration with Insilico Medicine in a deal valued up to $2.75 billion, extending a multi-year partnership that is intended to generate novel preclinical oral therapeutics across multiple therapeutic areas. Lilly will pay $115 million upfront, with development, regulatory, and commercial milestones contingent on progress. The agreement builds on Lilly’s broader AI investments and its push to translate AI-discovered candidates faster into development programs, particularly where differentiated chemistry and mechanism selection can reduce attrition. For investors and pipeline planners, the deal underscores that Lilly views external AI capacity as a strategic complement to its internal discovery and translational strengths.